Intellia Therapeutics
NTLA
283 hedge funds and large institutions have $1.92B invested in Intellia Therapeutics in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 113 increasing their positions, 86 reducing their positions, and 47 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 86
1.61% less ownership
Funds ownership: 93.41% → 91.8% (-1.6%)
2% less funds holding
Funds holding: 290 → 283 (-7)
5% less capital invested
Capital invested by funds: $2.02B → $1.92B (-$101M)
11% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 47
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
48% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $20.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$15.2M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$15M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$25.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.3M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$11.5M |
| 4 |
PA
Pinnacle Associates
New York
|
-$5.62M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$5.44M |
NTLA Hedge Fund Activity: Q3 2024 in Review
283 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2024, worth a combined $1.92B — down 5% from $2.02B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of NTLA and 42 opened new positions — a net loss of 5 holders — while 86 trimmed existing stakes and 113 added.
The largest buyer was State Street, adding an estimated $18M. The largest seller was Rokos Capital Management (UK), exiting entirely with an estimated $25.5M sold.
- 283 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2024, down from 290 in Q2 2024.
- Funds reported $1.92B of Intellia Therapeutics stock for Q3 2024, down 5% quarter-over-quarter.
- 42 funds opened new Intellia Therapeutics positions in Q3 2024 and 47 closed out, a net change of -5 holders.
- The largest Intellia Therapeutics buyer in Q3 2024 was State Street, an estimated $18M added.
- The largest Intellia Therapeutics seller in Q3 2024 was Rokos Capital Management (UK), an estimated $25.5M sold.
Based on aggregated 13F filings for Q3 2024.